Kepler Capital Keeps Their Hold Rating on Sanofi (SNYNF)

Kepler Capital analyst Christopher Richardson, CFA maintained a Hold rating on Sanofi (SNYNF – Research Report) on April 25 and set a price target of €92.00. The company’s shares closed last Thursday at $95.54.

According to TipRanks, Richardson, CFA is an analyst with an average return of -12.1% and a 0.00% success rate.

In addition to Kepler Capital , Sanofi also received a Hold from DZ BANK AG’s Elmar Kraus in a report issued on April 25. However, yesterday, Bank of America Securities reiterated a Buy rating on Sanofi (Other OTC: SNYNF).

The company has a one-year high of $114.90 and a one-year low of $86.12. Currently, Sanofi has an average volume of 36.91K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sanofi (SNYNF) Company Description:

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.